Fully vaccinated people with systemic rheumatic diseases have less severe COVID outcomes

Breakthrough COVID-19 had lower hospitalisation and mortality in vaccinated patients INTRODUCTION COVID-19 is the disease caused by a new type of coronavirus called severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). It was declared a pandemic by the World Health Organization on 11 March 2020. COVID-19 has forced people to change their behaviours to try to limit […]

Read More…

Cardiovascular risk management in rheumatic diseases

This is the lay version of the EULAR recommendations for managing cardiovascular risks in people with rheumatic and musculoskeletal diseases. The original publication can be downloaded from the EULAR website: www.eular.org. Drosos GC, Vedder D, Houben E, et al. EULAR recommendations for cardiovascular risk management in rheumatic and musculoskeletal diseases, including systemic lupus erythematosus and […]

Read More…

Managing gout

This is the lay version of the EULAR recommendations for the management of people with gout. The original publication can be downloaded from the EULAR website: www.eular.org. Richette P, et al. 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis 2017;76:29–42. doi:10.1136/annrheumdis-2016-209707 Introduction EULAR recommendations give advice to doctors, nurses and […]

Read More…

Treat-to-target could be a reality in gout

Targeting urate levels could help to improve care for people with gout. INTRODUCTION Gout is a very common condition, affecting up to 2% of adults in developed countries. The symptoms tend to flare every so often, developing over a few hours and causing severe pain in the joints. It is caused by deposits of crystals […]

Read More…